A $1.27 billion Parkinson’s licensing deal, an FDA meeting on the calendar, and a $6 million share offering priced on the same day a stock was up 76%: that is the mix of catalysts and caution in the penny stocks to watch tomorrow, Friday, October 9. All ten trade under $4, most are micro caps, and several have already run hard. Each section below gives the latest verified close, key levels, bull and bear cases and what to watch.
Penny Stocks to Watch Tomorrow: Thursday’s Market Snapshot
| Metric | Thursday Close / Reading |
|---|---|
| S&P 500 | 7,765.36 (-0.47%), second straight loss |
| Nasdaq Composite | 27,193.34 (-1.25%) |
| Dow Jones Industrial Average | 51,231.64 (+0.10%) |
| Russell 2000 | 2,794.13 (+0.03%), down 1.4% on the week |
| 10-Year Treasury Yield | ~5.23% at the close (near 5.35% intraday) |
| Oil | Surged more than 5% intraday on Persian Gulf tanker attacks |
The S&P 500 fell for a second straight session as the AI trade stumbled and yields stayed elevated, while the Russell 2000 held flat after sliding earlier in the day. Rising yields and oil are a standing headwind for unprofitable small caps.
Data note (please read): Closes are the most recent we could verify, and the date is shown in each table. For several names, a verified Thursday (Oct 8) close was not yet published, so the table shows the latest confirmed close instead. Intraday and after-hours snapshots can differ from final closes. Where sources disagreed we say “roughly” or “not confirmed.” Support and resistance levels are analytical zones, not guaranteed targets. Penny stocks are highly speculative.
1. Alector (ALEC) | Last Close $1.92 (+6.08%) | Roche’s $1.27 Billion Parkinson’s Bet
A $100 Million Check, a 70% Spike and a Pullback to the Mid-$1s
Genentech, a Roche unit, will pay Alector $100 million upfront and up to $1.17 billion more in milestones for AL050, an experimental Parkinson’s therapy, for a deal worth up to $1.27 billion.
| Metric | Value |
|---|---|
| Last Verified Close | $1.92 (Oct 7) |
| Previous Close | $1.81 (Oct 6) |
| Day’s Move | +6.08% (+$0.11) |
| Day’s Range | ~$1.73 – $1.91 (intraday, Oct 7) |
| 52-Week Range | $1.09 – $3.40 |
| Market Cap | Roughly $180M–$220M (feeds vary) |
| P/E / Dividend | N/A (loss-making) / None |
| Volume vs. Average | Oct 7 intraday ~2.8M vs. ~10.8M average |
| Recent Spike | Premarket +55% to ~$2.81 on Oct 5; close near $2.24 that day (early report) |
| Analyst View | Hold (7 analysts); average target $3.30 (~+72%) |
| Support 1 / 2 / 3 | $1.81 / $1.73 / $1.09 |
| Resistance 1 / 2 / 3 | ~$2.24 / ~$2.81 / $3.40 |
Catalyst & Latest News: Alector keeps its broader pipeline and is eligible for royalties. Investing.com notes the deal extends its cash runway and validates its blood-brain-barrier platform.
Technicals: The stock gave back most of the Oct 5 spike within two sessions, closing near $1.81 before Wednesday’s bounce. $1.81 is the line to hold.
Fundamentals: Cash and investments were near $206.5 million before the upfront payment, with a current ratio above 5, per StocksToTrade.
Bull Case: Big-pharma validation, a longer runway and a $3.30 average target. Bear Case: A Hold consensus, ongoing losses and a faded spike.
What to Watch:
- A hold above $1.81
- A move back toward $2.24
- Analyst target changes after the deal
Forecast: Holding $1.81 keeps $2.24 in play. Under $1.73, the next level is $1.09.
Why This Matters: ALEC is the best-funded, best-validated name on this list, and the one with the clearest fundamental support.
2. Sunshine Biopharma (SBFM) | Last Close $0.70 (+75.9%) | 178 Million Shares Then a $6M Offering
The Textbook Spike-and-Raise: Up 76% Wednesday, Offering Priced Thursday
Sunshine Biopharma surged 75.9% on Wednesday on roughly 178 million shares, and announced the pricing of a $6.0 million public offering on Thursday morning.
| Metric | Value |
|---|---|
| Last Verified Close | $0.70 (Oct 7) |
| Previous Close | ~$0.40 (Oct 6; derived) |
| Day’s Move | +75.9% |
| Day’s Range | Not confirmed |
| 52-Week Range | Not confirmed |
| Market Cap | ~$2.7M (Oct 7 board) |
| P/E / Dividend | N/A / None |
| Volume vs. Average | ~178M (Oct 7); average not confirmed |
| Oct 8 Price Reaction | Not confirmed |
| Analyst View | No coverage located |
| Support 1 / 2 / 3 | ~$0.40 / ~$0.30 / ~$0.20 |
| Resistance 1 / 2 / 3 | $0.70 / ~$1.00 / ~$1.25 |
Catalyst & Latest News: The offering was priced Thursday at 8:00 AM ET, per Stock Titan. We could not confirm the per-share price or Thursday’s close.
Technicals: A single-session 76% spike on extreme volume usually sets up a gap fill. The prior close near $0.40 is the downside reference.
Fundamentals: With a market cap near $2.7 million and a fresh $6 million raise, the offering is large relative to the company, which implies heavy dilution.
Bull Case: Fresh cash extends the runway and the volume is real. Bear Case: Dilution, a spike that already priced in the news, and thin fundamentals.
What to Watch:
- Thursday’s close versus the offering price
- Warrant terms in the filing
- A hold above $0.40
Forecast: Offerings priced into a spike often pull the stock back toward the pre-spike close. A fade toward $0.40 is the base case; holding $0.70 would be a surprise.
Why This Matters: SBFM is a risk-management lesson: a 76% day and a dilutive raise within 24 hours.
3. IRIDEX (IRIX) | Last Close $0.878 (+29.2%) | A Medical-Laser Micro Cap Wakes Up
Insider Buying, a Factory Move and a 29% Wednesday
IRIDEX gained 29.2% on Wednesday to $0.878, with an after-hours bid near $0.95, after opening that session near $0.68.
| Metric | Value |
|---|---|
| Last Verified Close | $0.878 (Oct 7); after-hours ~$0.95 (+8.2%) |
| Previous Close | ~$0.68 (Oct 6) |
| Day’s Move | +29.2% |
| Day’s Range | Not confirmed |
| 52-Week Range | $0.61 – $1.65 |
| Market Cap | ~$15.4M |
| P/E / Dividend | About -3.4x at $0.68 / None |
| Volume vs. Average | ~19.8M on Oct 7; average not confirmed |
| Moving Averages | 50-day $0.73 / 200-day $0.95 |
| Analyst View | One Buy, one Sell; average target about $2.75–$3.00 |
| Support 1 / 2 / 3 | $0.73 / ~$0.68 / $0.61 |
| Resistance 1 / 2 / 3 | $0.95 / ~$1.00 / $1.65 |
Catalyst & Latest News: We found no single headline for Wednesday’s jump. Recent items include a completed factory move to San Jose targeting $0.6 million in annual savings and continued insider purchases by a major shareholder, per Defense World.
Technicals: The stock cleared its 50-day average and ran into the 200-day near $0.95, which is where the after-hours bid sat.
Fundamentals: Q2 revenue was $12.57 million versus a $13.59 million estimate, with analysts expecting a loss of about $0.12 per share this year.
Bull Case: Insider accumulation, cost cuts and targets well above the price. Bear Case: A revenue miss, no confirmed catalyst for the spike and a stock still near its lows.
What to Watch:
- The $0.95 200-day area
- A hold above $0.73
- New Form 4 filings
Forecast: A close above $0.95 opens $1.00. A slide under $0.73 puts the move at risk.
Why This Matters: IRIX shows how insider buying and a technical breakout can lift a micro cap with no headline.
4. Netcapital (NCPL) | Last Close $1.59 (+45.9%) | Back Above $1, With Baggage
A 46% Jump, a Nasdaq Deadline and a Convertible-Note Overhang
Netcapital rose 45.9% on Wednesday to $1.59 on about 12.3 million shares.
| Metric | Value |
|---|---|
| Last Verified Close | $1.59 (Oct 7) |
| Previous Close | ~$1.09 (Oct 6; derived) |
| Day’s Move | +45.9% |
| Day’s Range | Not confirmed |
| 52-Week Range | $0.31 – $8.75 (as of mid-2026 sources) |
| Market Cap | ~$12.5M (Oct 7 board) |
| P/E / Dividend | Negative / None |
| Volume vs. Average | ~12.3M vs. a multi-million average (varies by source) |
| Analyst View | No coverage located |
| Support 1 / 2 / 3 | ~$1.09 / $1.00 / ~$0.85 |
| Resistance 1 / 2 / 3 | ~$1.79 / $2.00 / ~$2.75 |
Catalyst & Latest News: Quiver Quantitative notes that no single fresh catalyst was obvious in an earlier spike, pointing to a Nasdaq extension through February 1, 2027 to regain the $1.00 bid rule and amended convertible notes. We found no confirmed news for Wednesday.
Technicals: A close above $1.00 matters for its listing. Nasdaq’s standard cure is ten consecutive closes at or above $1.00.
Fundamentals: The company has a new CEO and an SEC civil complaint it has publicly addressed, per the same report.
Bull Case: A reclaim of $1 helps its listing case, and the stock has a history of sharp rebounds. Bear Case: Convertible-note dilution, regulatory overhang and no confirmed catalyst.
What to Watch:
- Whether $1.00 holds on a pullback
- Any new note conversions or financings
- Nasdaq compliance updates
Forecast: Holding $1.09 keeps $1.79 in view. Under $1.00, the rally likely fully reverses.
Why This Matters: NCPL is a listing-risk trade where the $1 line is the whole story.
5. PDS Biotechnology (PDSB) | Last Verified Close $1.20 (+60.3%) | The Oncology Name Up 400% in a Month
Monday’s Final Print Was Even Bigger Than the Midday Snapshot
PDSB closed Monday at about $1.20, up 60.3% from $0.75, per a Chartmill movers board, on roughly 78 million shares. This corrects the $1.07 midday figure in our October 5 penny list.
| Metric | Value |
|---|---|
| Last Verified Close | ~$1.20 (Oct 5); Oct 6–8 prints not confirmed |
| Previous Close | $0.75 (Oct 2) |
| Day’s Move | +60.3% |
| Day’s Range | Intraday high near $1.18 in earlier snapshots; final range not confirmed |
| 52-Week Range | $0.20 – $1.54 |
| Market Cap | Roughly $75M–$84M (sources vary) |
| P/E / Dividend | N/A / None |
| Volume vs. Average | ~78M vs. ~21M average |
| Analyst View | Strong Buy (3 analysts); average target $4.75; MarketBeat consensus Hold |
| Support 1 / 2 / 3 | ~$1.07 / $0.75 / ~$0.28 |
| Resistance 1 / 2 / 3 | $1.54 / $2.00 / ~$2.50 |
Catalyst & Latest News: The company refocused on PDS0301 in metastatic colorectal cancer and closed an initial PIPE financing of up to $22.3 million that brought Dr. Patrick Soon-Shiong onto the board. We could not pin one trigger for Monday.
Technicals: The stock rose from near $0.28 in early September to above $1. The $0.75 gap is the key downside marker.
Fundamentals: Clinical-stage with no product revenue and a 2026 EPS estimate near -$0.49.
Bull Case: New financing, a focused pipeline and a $4.75 average target. Bear Case: A 4x run in a month and persistent dilution risk.
What to Watch:
- The $1.54 52-week high
- A hold above $0.75
- Clinical updates on PDS0301
Forecast: A close above $1.54 would open $2.00. Under $1.07, the move starts to unwind.
Why This Matters: PDSB is the best-known momentum biotech on the list, and a big move either way is likely.
6. QTREX Quantum (QTEX) | Last Verified Close ~$1.59 | Up Roughly 133% in a Week
From $0.68 to $1.59 With a Binding Deal Expected “Within Weeks”
QTREX closed Monday at $1.54 (+40%) and traded near $1.59 on Tuesday’s weekly board. This corrects the $1.29 figure in our October 5 list.
| Metric | Value |
|---|---|
| Last Verified Close | ~$1.59 (Oct 6, per StockAnalysis); Oct 7–8 not confirmed |
| Previous Close | $1.54 (Oct 5) |
| Day’s Move | ~+3% (Oct 6) |
| Day’s Range | Premarket high ~$1.77 on Oct 6 |
| 52-Week Range | Not confirmed |
| Market Cap | ~$88.6M |
| P/E / Dividend | N/A / None |
| Volume vs. Average | ~71M (Oct 6) |
| 1-Week Move | +133% |
| Analyst View | No Wall Street targets located |
| Support 1 / 2 / 3 | $1.54 / $1.10 / ~$0.90 |
| Resistance 1 / 2 / 3 | $1.77 / $1.97 / ~$2.50 |
Catalyst & Latest News: TipRanks reported independent tests showing more than 100 dB of isolation at 20 millikelvin. A binding agreement with an unnamed quantum company is expected within weeks.
Technicals: The stock gapped from the $0.70–$0.90 range to above $1.50 in three sessions. A close under $1.54 would erase Monday’s gains.
Fundamentals: Cash was roughly $3.2 million at last report, which is thin for the valuation.
Bull Case: A signed deal could validate the technology. Bear Case: A missed timeline or an equity raise.
What to Watch:
- The deal announcement
- A hold above $1.54
- Offering or ATM language
Forecast: A confirmed deal could test $1.97. A slip under $1.54 targets $1.10.
Why This Matters: QTEX is a headline-or-bust quantum play.
7. HeartBeam (BEAT) | Last Verified Close $0.6542 (+50.5%) | FDA Breakthrough Designation
A Heart-Attack Detection Tool, 403 Million Shares and a 90% Intraday Spike
HeartBeam closed Monday at $0.6542, up 50.53%, on about 403 million shares after the FDA granted Breakthrough Device Designation.
| Metric | Value |
|---|---|
| Last Verified Close | $0.6542 (Oct 5); later prints not confirmed |
| Previous Close | $0.4346 (Oct 2) |
| Day’s Move | +50.5% (intraday high near +90%) |
| Day’s Range | Not confirmed (high near $0.83) |
| 52-Week Range | Low $0.36 (Sep 24); high above $1.30 |
| Market Cap | ~$38M |
| P/E / Dividend | N/A / None |
| Volume vs. Average | ~403M vs. ~625K average |
| Analyst View | Thin coverage; no consensus located |
| Support 1 / 2 / 3 | $0.55 / $0.43 / $0.36 |
| Resistance 1 / 2 / 3 | ~$0.72 / ~$0.83 / ~$0.94–$0.99 |
Catalyst & Latest News: The FDA acted within 30 days of the request. A 134-patient pilot comes before a pivotal study.
Technicals: The gap cleared a $0.36–$0.45 base. A weekly board later showed the stock near $0.58 on Oct 6, so some of the spike has already faded (unconfirmed).
Fundamentals: The heart-attack program uses the same 3D ECG platform as its cleared arrhythmia product, but it has minimal revenue and recurring losses.
Bull Case: Regulatory validation and a large addressable market. Bear Case: Designation is not clearance, and micro caps often raise capital after spikes.
What to Watch:
- A hold above $0.55
- Financing news
- Pivotal-study design
Forecast: Holding $0.55 keeps $0.72 in play. A close under $0.43 erases the gap.
Why This Matters: BEAT is the cleanest regulatory-catalyst story, and the most exposed to dilution.
8. Cognition Therapeutics (CGTX) | Last Close Roughly $0.91 | FDA Meeting October 20
The Dated Catalyst: A Phase 3 Endpoint Meeting 12 Days Out
H.C. Wainwright reiterated Buy with a $3.00 target ahead of a Type C FDA meeting set for October 20.
| Metric | Value |
|---|---|
| Last Verified Close | Roughly $0.91 (Oct 5; implied by an $88M market cap, not confirmed) |
| Previous Close | Roughly $0.94 (Sep 29) |
| Day’s Move | Not confirmed |
| Day’s Range | Not confirmed |
| 52-Week Range | $0.55 – $2.57 (as of Sept 10) |
| Market Cap | ~$88M |
| P/E / Dividend | N/A / None |
| Volume vs. Average | Not confirmed |
| Analyst View | H.C. Wainwright Buy, $3.00 target |
| Support 1 / 2 / 3 | $0.88 / $0.75 / $0.55 |
| Resistance 1 / 2 / 3 | $0.98 / $1.50 / $2.57 |
Catalyst & Latest News: Cognition said the Division of Neurology meeting will align on endpoints and statistics for a Phase 3 zervimesine study in dementia with Lewy bodies psychosis.
Technicals: The stock has held a narrow $0.90–$0.99 range for weeks, which makes October 20 a potential range-break event.
Fundamentals: The current ratio is about 7.0 and the Q2 net loss narrowed. A pivotal start is expected in mid-2027.
Bull Case: FDA alignment would de-risk Phase 3. Bear Case: A vague outcome could disappoint, and the pivotal trial is still far off.
What to Watch:
- The October 20 readout
- A hold above $0.88
- Phase 3 funding plans
Forecast: Run-up trading into the meeting can test $0.98–$1.00. A negative headline risks $0.75.
Why This Matters: CGTX is a rare dated catalyst among penny stocks.
9. Sable Offshore (SOC) | Last Verified Close $3.47 (-1.14%) | Wall Street Piles In
Under $4 With a Q4 Restart and a $10 JPMorgan Target
JPMorgan initiated at Overweight with a $10 target, and Sable expects to restart its Hondo platform in the fourth quarter.
| Metric | Value |
|---|---|
| Last Verified Close | $3.47 (Oct 5); Tuesday intraday ~$3.57 |
| Previous Close | $3.51 (Oct 2, +6.69%) |
| Day’s Move | -1.14% (Oct 5) |
| Day’s Range | $3.36 – $3.64 (Oct 5) |
| 52-Week Range | $2.88 (June 30) – $20.74 (Oct 10, 2025) |
| Market Cap | ~$673M–$695M |
| P/E / Dividend | About -1.1x / None |
| Volume vs. Average | Oct 5: 6.70M; Oct 2: 10.47M |
| YTD | About -61.5% |
| Analyst View | 5 Buy, 1 Hold, 2 Sell; JPMorgan $10, Stifel $8, Roth $10 |
| Support 1 / 2 / 3 | ~$3.42 / $3.29 / $2.88 |
| Resistance 1 / 2 / 3 | $3.64 / ~$4.00 / ~$8.00 |
Catalyst & Latest News: MarketScreener tracks the Hondo restart timeline and the analyst initiations. Oil’s 5% jump Thursday is a tailwind.
Technicals: SOC sits near the low end of its range and well under its 200-day average.
Fundamentals: It is selling oil but remains loss-making.
Bull Case: Consensus targets near $9.60 and a restart adding barrels. Bear Case: Operating and regulatory hurdles, losses and two Sell ratings.
What to Watch:
- A close above $3.64
- Hondo restart timing
- Crude oil moves
Forecast: A break over $3.64 targets $4.00. Under $3.29, the $2.88 low is exposed.
Why This Matters: SOC is the largest-cap name here and a levered play on oil and a restart.
10. Humacyte (HUMA) | Last Close Near $0.50 | A $144 Million Biotech at Its 52-Week Low
An Approved Product, Tiny Sales and a November Filing
Humacyte sits near its 52-week low of about $0.50, against a $2.55 high.
| Metric | Value |
|---|---|
| Last Verified Close | Near $0.50 (Oct 5–6; not confirmed to the cent) |
| Previous Close | ~$0.52 (Oct 2) |
| Day’s Move | Roughly -4% |
| Day’s Range | Oct 2: $0.50 – $0.53 |
| 52-Week Range | $0.50 – $2.55 |
| Market Cap | ~$144.5M |
| P/E / Dividend | -1.07 / None |
| Volume vs. Average | Oct 2: 5.4M vs. 3.85M average |
| Analyst View | Buy (5 analysts); average target $1.85 |
| Support 1 / 2 / 3 | $0.50 / $0.45 / $0.40 |
| Resistance 1 / 2 / 3 | $0.53 / $0.64 / $1.00 |
Catalyst & Latest News: A supplemental BLA for dialysis access is planned for November 2026, and the FDA extended Symvess shelf life to 36 months.
Technicals: Lower highs since the Q2 report. A break of $0.50 means price discovery with no support.
Fundamentals: Q1 Symvess sales were just $0.5 million (29 units), and Q2 missed estimates badly.
Bull Case: An approved product and a dialysis filing. Bear Case: Tiny sales, repeated misses and a sub-$1 price that invites a Nasdaq deficiency notice if it persists.
What to Watch:
- $0.50 as support
- Dialysis sBLA timing
- Q3 results in early November
Forecast: A close above $0.64 begins a recovery. Under $0.50, $0.45 and $0.40 are next.
Why This Matters: HUMA is the “approved but not selling” case study in commercial biotech.
Penny Stocks Sector Snapshot and Forecast: Catalysts Are Doing the Work
Biotech and medtech (ALEC, PDSB, BEAT, CGTX, HUMA, SBFM) dominate the list, with outcomes tied to financing and regulatory dates. QTEX is a quantum-hype trade, SOC is an oil-and-restart story, and IRIX and NCPL are technical rebounds with no confirmed news. The Russell 2000’s 1.4% weekly loss and a 5.2%-plus 10-year yield argue for tight risk control. For earlier small-cap setups, see our July 17 penny stocks list, our Capricor Therapeutics forecast for a biotech catalyst example, and our top trending stocks from September 2. Sector forecast: Expect dated catalysts (CGTX on October 20, HUMA in November) to attract positioning, and spike-then-raise names (SBFM) to stay vulnerable.
Penny Stocks Under $4 At a Glance
| # | Ticker | Last Verified Close | Move | Market Cap | Catalyst | Support | Resistance | Bias |
|---|---|---|---|---|---|---|---|---|
| 1 | ALEC | $1.92 (Oct 7) | +6.08% | ~$180–220M | Roche/Genentech $1.27B deal | $1.81 | ~$2.24 | Hold support |
| 2 | SBFM | $0.70 (Oct 7) | +75.9% | ~$2.7M | $6M offering priced Oct 8 | ~$0.40 | $0.70 | Dilution risk |
| 3 | IRIX | $0.878 (Oct 7) | +29.2% | ~$15.4M | Insider buying, cost cuts | $0.73 | $0.95 | Technical test |
| 4 | NCPL | $1.59 (Oct 7) | +45.9% | ~$12.5M | No confirmed news | $1.00 | ~$1.79 | Speculative |
| 5 | PDSB | ~$1.20 (Oct 5) | +60.3% | ~$75–84M | PDS0301 focus, PIPE | ~$1.07 | $1.54 | Extended |
| 6 | QTEX | ~$1.59 (Oct 6) | ~+3% | ~$88.6M | Quantum deal expected | $1.54 | $1.77 | Headline-driven |
| 7 | BEAT | $0.6542 (Oct 5) | +50.5% | ~$38M | FDA Breakthrough | $0.55 | ~$0.72 | Fade risk |
| 8 | CGTX | ~$0.91 (Oct 5) | n/a | ~$88M | FDA meeting Oct 20 | $0.88 | $0.98 | Dated catalyst |
| 9 | SOC | $3.47 (Oct 5) | -1.14% | ~$673–695M | Analyst initiations, Hondo | $3.29 | $3.64 | Range-bound |
| 10 | HUMA | ~$0.50 (Oct 5–6) | ~-4% | ~$144.5M | Dialysis sBLA (Nov) | $0.50 | $0.64 | Watch support |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and penny stocks and micro-cap names carry elevated risk, including extreme volatility, thin liquidity, dilution and delisting risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
